Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2013 Dec 1;64(4):10.1097/QAI.0b013e3182a7adb2. doi: 10.1097/QAI.0b013e3182a7adb2

Table 2. Distribution of Maternal TDF Use in Pregnancy among the Infant Study Population by Weight at Birth (N=2025) and 6-months of Age (N=1496).

Characteristics Birth weight Weight at 6 months of age
Total
(N=2025)		 Age and sex
adjusted z-
score <5%
(N=98)		 Age and sex
adjusted z-
score <10%
(N=225)		 Total
(N=1496)		 Age and sex
adjusted z-
score <5%
(N=61)
TDF use during pregnancy
 Unexposed 1,395 (69%) 69 (70%) 153 (68%) 1,039 (69%) 37 (61%)
 Exposed 630 (31%) 29 (30%) 72 (32%) 457 (31%) 24 (39%)
Trimester of 1st reported TDF
exposure
 1st Trimester 418 (21%) 20 (20%) 45 (20%) 302 (20%) 12 (20%)
 2nd or 3rd Trimester 212 (10%) 9 (9%) 27 (12%) 155 (10%) 12 (20%)
 Unexposed 1,395 (69%) 69 (70%) 153 (68%) 1,039 (69%) 37 (61%)
Duration of TDF exposure during
pregnancy
 < 4 weeks 40 (2%) 2 (2%) 4 (2%) 28 (2%) 2 (3%)
 4 - 12 weeks 124 (6%) 5 (5%) 11 (5%) 101 (7%) 6 (10%)
 >12 weeks 466 (23%) 22 (22%) 57 (25%) 328 (22%) 16 (26%)
 Unexposed 1,395 (69%) 69 (70%) 153 (68%) 1,039 (69%) 37 (61%)